No-Spa (Drotaverine Hydrochloride)

Drotaverine blocks phosphodiesterase‑4 enzymes, which raises intracellular cyclic AMP levels. The increase in cAMP leads to relaxation of smooth muscle cells and vasodilation, thereby reducing spasm and improving blood flow in the affected area.

The specific dose of No‑Spa is determined by the prescribing clinician based on the patient’s condition, weight, age, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal relief while minimizing potential adverse effects.

Safety data for drotaverine during pregnancy and lactation are limited. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request No‑Spa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with anticholinergic agents, drotaverine acts via phosphodiesterase inhibition rather than muscarinic blockade, which often results in fewer anticholinergic side effects such as dry mouth or blurred vision. Its rapid onset after injection can be advantageous in acute spasm situations.

Store No‑Spa below 25 °C in its original packaging, protecting it from light and moisture. Avoid freezing the product and ensure that any reconstituted solution is used within the time frame recommended by the manufacturer.

No‑Spa is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site, and infusion rate are selected by the treating clinician according to the clinical situation and patient tolerance.

Serious adverse events, although rare, include anaphylactic reactions, severe hypotension and significant elevations in liver enzymes. Immediate medical attention is required if any signs of allergic reaction, sudden drop in blood pressure, or jaundice develop.

Patients with known hypersensitivity to drotaverine or any component of the formulation should avoid No‑Spa. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled hypertension, or significant hepatic impairment, and the drug should be used only under medical supervision in these groups.